NASDAQ: MESO
Mesoblast Ltd Stock

$11.40-0.51 (-4.28%)
Updated Apr 30, 2025
MESO Price
$11.40
Fair Value Price
-$9.07
Market Cap
$1.31B
52 Week Low
$5.78
52 Week High
$22.00
P/E
-12.27x
P/B
2.85x
P/S
398.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.67M
Earnings
-$103.35M
Gross Margin
100%
Operating Margin
-1,405.84%
Profit Margin
-1,822.8%
Debt to Equity
0.42
Operating Cash Flow
-$43M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MESO Overview

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine MESO's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
MESO
Ranked
#78 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important MESO news, forecast changes, insider trades & much more!

MESO News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MESO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MESO ($11.40) is overvalued by 225.67% relative to our estimate of its Fair Value price of -$9.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MESO ($11.40) is not significantly undervalued (225.67%) relative to our estimate of its Fair Value price of -$9.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MESO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MESO due diligence checks available for Premium users.

Valuation

MESO fair value

Fair Value of MESO stock based on Discounted Cash Flow (DCF)

Price
$11.40
Fair Value
-$9.07
Undervalued by
225.67%
MESO ($11.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MESO ($11.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MESO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MESO price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-12.27x
Industry
-162.28x
Market
29.18x

MESO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.85x
Industry
4.45x
MESO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MESO's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MESO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MESO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$653.3M
Liabilities
$192.1M
Debt to equity
0.42
MESO's short-term liabilities ($72.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MESO's long-term liabilities ($119.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MESO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MESO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
MESO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MESO vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
MESOC$1.31B-4.28%-12.27x2.85x
ARDXC$1.31B+1.01%-32.38x7.57x
OCULC$1.32B+1.10%-6.80x4.19x
DYNF$1.33B+0.60%-3.50x2.12x
SPRYC$1.37B+0.36%174.63x5.34x

Mesoblast Stock FAQ

What is Mesoblast's quote symbol?

(NASDAQ: MESO) Mesoblast trades on the NASDAQ under the ticker symbol MESO. Mesoblast stock quotes can also be displayed as NASDAQ: MESO.

If you're new to stock investing, here's how to buy Mesoblast stock.

What is the 52 week high and low for Mesoblast (NASDAQ: MESO)?

(NASDAQ: MESO) Mesoblast's 52-week high was $22.00, and its 52-week low was $5.78. It is currently -48.18% from its 52-week high and 97.23% from its 52-week low.

How much is Mesoblast stock worth today?

(NASDAQ: MESO) Mesoblast currently has 1,152,444,429 outstanding shares. With Mesoblast stock trading at $11.40 per share, the total value of Mesoblast stock (market capitalization) is $1.31B.

Mesoblast stock was originally listed at a price of $16.22 in Nov 13, 2015. If you had invested in Mesoblast stock at $16.22, your return over the last 9 years would have been -29.72%, for an annualized return of -3.84% (not including any dividends or dividend reinvestments).

How much is Mesoblast's stock price per share?

(NASDAQ: MESO) Mesoblast stock price per share is $11.40 today (as of Apr 30, 2025).

What is Mesoblast's Market Cap?

(NASDAQ: MESO) Mesoblast's market cap is $1.31B, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Mesoblast's market cap is calculated by multiplying MESO's current stock price of $11.40 by MESO's total outstanding shares of 1,152,444,429.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.